This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
by Zacks Equity Research
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
3 Medical Instruments Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.
IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 16.42% and 5.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why IDEXX Laboratories (IDXX) Might Surprise This Earnings Season
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fiscal second-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Idexx (IDXX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's How Much a $1000 Investment in Idexx Laboratories Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why You Should Add Teleflex (TFX) to Your Portfolio
by Zacks Equity Research
Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).
IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
LabCorp (LH) Expands Testing Portfolio With the Launch of CDx
by Zacks Equity Research
LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
by Zacks Equity Research
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
Pandemic Boosts Animal Health Spending: 4 Stocks to Buy
by Riya Anand
Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.
Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line
by Zacks Equity Research
Penumbra (PEN) to initiate commercialization of RED 62 Reperfusion Catheter post FDA clearance.
NEOGEN (NEOG) Enhances Aquaculture Genotyping With New Pact
by Zacks Equity Research
NEOGEN (NEOG) together with CAT can enable members of the aquaculture sector to make more informed breeding decisions.
LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research
by Zacks Equity Research
The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.